Epstein-Barr virus (EBV) infection and associated post transplantation lymphoproliferative disease (PTLD) in hematopoietic stem cell transplantation (HSCT): a prevalence based systematic review and meta-analysis on global epidemiology.
Awais Mustafa, Shahad Saif Khandker, Umme Farwa, Muhammad Hamza Saeed, Muhammad Sarfraz, Abdul Manan, Hifza Ishtiaq Gillani, Amna Akbar, Khawaja Faizan Ejaz, Asma Atta, Maryam Atta, Alif Hasan Pranto, Brian Gomes, Anikah Lubaba, Thamjeed Mohaimeen, Shifaty Nur Abir, Mohammad Saleem Khan
{"title":"Epstein-Barr virus (EBV) infection and associated post transplantation lymphoproliferative disease (PTLD) in hematopoietic stem cell transplantation (HSCT): a prevalence based systematic review and meta-analysis on global epidemiology.","authors":"Awais Mustafa, Shahad Saif Khandker, Umme Farwa, Muhammad Hamza Saeed, Muhammad Sarfraz, Abdul Manan, Hifza Ishtiaq Gillani, Amna Akbar, Khawaja Faizan Ejaz, Asma Atta, Maryam Atta, Alif Hasan Pranto, Brian Gomes, Anikah Lubaba, Thamjeed Mohaimeen, Shifaty Nur Abir, Mohammad Saleem Khan","doi":"10.1080/14737140.2025.2557615","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hematopoietic stem cell transplantation (HSCT) is a widely used transplant method for different cancerous and non-cancerous conditions, particularly when conventional treatments fail. Again, Epstein-Barr Virus (EBV), one of the major contributors to gastric carcinoma can cause post-transplantation lymphoproliferative disease (PTLD) after transplantations. However, the global prevalence of EBV infection and associated PTLD in HSCT recipients is yet to be determined.</p><p><strong>Methods: </strong>This research examined 33 studies selected from 941 articles across three databases (i.e. ScienceDirect, PubMed, and Google Scholar) to investigate the global epidemiology of EBV infection and associated PTLD in HSCT patients.</p><p><strong>Results: </strong>The overall prevalence was calculated primarily as 27.0%; 95% CI: 24.5-29.5, and 23.7%; 95% CI: 19.3-28.3 after removing outlier studies. The analyzed studies were of high quality. Among different continents, North America was determined to have the highest prevalence rate (33.3%; 95%CI: 12.5-54.1) followed by Europe (27.8%; 95%CI: 23.3-32.2), and Asia (20.7%; 95%CI: 17.4-23.9).</p><p><strong>Conclusion: </strong>This investigation highlights the need for early detection of EBV infection and associated PTLD, personalized treatment strategies, and continued research into the condition's underlying mechanisms. Addressing these aspects can enhance outcomes for HSCT patients and contribute to advancements in transplant medicine.</p><p><strong>Registration: </strong>PROSPERO (CRD420250583221).</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-13"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2557615","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Hematopoietic stem cell transplantation (HSCT) is a widely used transplant method for different cancerous and non-cancerous conditions, particularly when conventional treatments fail. Again, Epstein-Barr Virus (EBV), one of the major contributors to gastric carcinoma can cause post-transplantation lymphoproliferative disease (PTLD) after transplantations. However, the global prevalence of EBV infection and associated PTLD in HSCT recipients is yet to be determined.
Methods: This research examined 33 studies selected from 941 articles across three databases (i.e. ScienceDirect, PubMed, and Google Scholar) to investigate the global epidemiology of EBV infection and associated PTLD in HSCT patients.
Results: The overall prevalence was calculated primarily as 27.0%; 95% CI: 24.5-29.5, and 23.7%; 95% CI: 19.3-28.3 after removing outlier studies. The analyzed studies were of high quality. Among different continents, North America was determined to have the highest prevalence rate (33.3%; 95%CI: 12.5-54.1) followed by Europe (27.8%; 95%CI: 23.3-32.2), and Asia (20.7%; 95%CI: 17.4-23.9).
Conclusion: This investigation highlights the need for early detection of EBV infection and associated PTLD, personalized treatment strategies, and continued research into the condition's underlying mechanisms. Addressing these aspects can enhance outcomes for HSCT patients and contribute to advancements in transplant medicine.
期刊介绍：
Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
